WallStreetZenWallStreetZen

NASDAQ: TRAW
Traws Pharma Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their TRAW stock forecasts and price targets.

Forecast return on equity

Is TRAW forecast to generate an efficient return?

Company
-2,689.42%
Industry
140.91%
Market
90.47%
TRAW's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is TRAW forecast to generate an efficient return on assets?

Company
-846.48%
Industry
32.45%
TRAW is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

TRAW earnings per share forecast

What is TRAW's earnings per share in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$33.75

TRAW revenue forecast

What is TRAW's revenue in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
$230.0k+1.32%
TRAW's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

TRAW revenue growth forecast

How is TRAW forecast to perform vs Biotechnology companies and vs the US market?

Company
11.14%
Industry
56.38%
Market
9.68%
TRAW's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
TRAW's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

TRAW vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TRAW$1.69N/AN/A
BTAI$1.56$49.25+3,057.05%Buy
ERNA$2.25N/AN/A
CAPS$1.79N/AN/A
CANF$1.07$10.00+834.58%Strong Buy
View Top Biotech Stocks

Traws Pharma Stock Forecast FAQ

What is TRAW's earnings growth forecast for 2025-2025?

(NASDAQ: TRAW) Traws Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.

Traws Pharma's earnings in 2025 is -$34,608,000.

In 2025, TRAW is forecast to generate -$187,795,631 in earnings, with the lowest earnings forecast at -$187,795,631 and the highest earnings forecast at -$187,795,631.

If you're new to stock investing, here's how to buy Traws Pharma stock.

What is TRAW's revenue growth forecast for 2025-2025?

(NASDAQ: TRAW) Traws Pharma's forecast annual revenue growth rate of 11.14% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.

Traws Pharma's revenue in 2025 is $227,000.

In 2025, TRAW is forecast to generate $1,279,792 in revenue, with the lowest revenue forecast at $1,279,792 and the highest revenue forecast at $1,279,792.

What is TRAW's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: TRAW) forecast ROA is -846.48%, which is lower than the forecast US Biotechnology industry average of 32.45%.

What is TRAW's Earnings Per Share (EPS) forecast for 2025-2025?

(NASDAQ: TRAW) Traws Pharma's current Earnings Per Share (EPS) is -$32.73. In 2025, TRAW's EPS is forecast to hit -$33.75 (min: -$33.75, max: -$33.75).

What is TRAW's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: TRAW) forecast ROE is -2,689.42%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.